Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

ClinicalTrials.gov ID: NCT00902928

Public ClinicalTrials.gov record NCT00902928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.

Study identification

NCT ID
NCT00902928
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Enrollment
1,992 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
May 31, 2010
Completion
Jul 31, 2010
Last update posted
Oct 26, 2015

2009 – 2010

United States locations

U.S. sites
18
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
Not listed Phoenix Arizona 85023
Not listed Phoenix Arizona 85050
Not listed Tuscon Arizona 85712
Not listed Little Rock Arkansas 72205
Not listed Long Beach California 90806
Not listed Torrance California 90507
Not listed Aurora Colorado 80015
Not listed DeLand Florida 32720
Not listed Pinellas Park Florida 33781
Not listed Sarasota Florida 34239
Not listed Tamarac Florida 33321
Not listed Meridian Idaho 83642
Not listed Lexington Kentucky 40509
Not listed Baltimore Maryland 21215
Not listed Charleston South Carolina 29414
Not listed Austin Texas 78745
Not listed Dallas Texas 75231
Not listed Houston Texas 77024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 138 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00902928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2015 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00902928 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →